Background: The use of left ventricular assist devices (LVAD) to support non-transplant candidates is controversial. We reviewed a large bridge-to-transplant database and found patients (pts) who were poor transplant candidates by virtue of advanced age or significant end-organ dysfunction. The goal of this analysis was to assess the efficacy of LVAD support in this population. Methods: We retrospectively reviewed the clinical data of the 225 pts enrolled in a US bridge-to-transplant trial. All patients had evidence of cardiogenic shock and high cardiac filling pressures despite optimal medical therapy. High-dose inotropic medications and intraaortic balloon counterpulsation also satisfied inclusion criteria. Low-risk recipients (LRR; n=146) were < 65 years of age and had a BUN < 100 mg/dl, Cr <2.5 mg/dl, bilirubin < 5.0 mg/dl, negative blood cultures and a pulmonary vascular resistance < 480 dyne sec/cm 5 . High-risk recipients (HRR; n=44) had at least one value discordant with those listed above. A control group (Co; n=35) was identified that met LVAD criteria but did not receive a device as a result of pt preference, device unavailability, or a mechanical aortic valve. Intergroup comparisons were analyzed using a student's t-test with p<0.05 considered significant. Kaplan-Meier analysis was used to estimate survival using log-rank test to assess significance. Results: Compared to LRR, the HRR had a lower mean blood pressure (63.9 vs 69.2, p<0.02), a higher pulmonary vascular resistance (282 vs 219, p=0.01), a higher BUN and Cr (52 vs 31, p <0.05; 2.3 vs 1.3, p=0.003), and a higher bilirubin (2.2 vs 1.5, p=0.003). The median survival was 11 days in Co vs 197 days in HRR vs 467 in LRR. The HRR survival at 30-, 60-, and 90-days was lower than LRR (77%, 72%, 68% vs 89%, 83%, 80%; p=0.02). The median survival of both LVAD groups was statistically superior to Co (p<0.0001). Conclusions: 1) Nearly 25% of the bridge-to-transplant LVAD implantation occurs in HRR who are poor transplant candidates. 2) The early post-implant mortality is predictably higher in HRR 3). Regardless of age and comorbidities, LVAD treated pts had superior survival compared to those managed with optimal medical therapy.
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Background Mortality in cardiogenic shock (CS)following acute myocardial infarction (AMI) remains at an unacceptable level despite PCI and use of intraaortic balloon counterpulsation. Frequently patients succumb to low output before the myocardium is able to recover from the ischemic event. A newly developed percutaneous left ventricular assist device (VAD) (Tandem Heart™ , Cardiac Assist Inc., Pittsburgh, PA, USA) with active circulatory support might decrease mortality.
Methods and results
Since 08/2000 patients in CS after an AMI with revascularization of the infarct related artery were randomized to either IABP (n=20) or percutaneous VAD support (n=19). Predicted mortality probability was similar in both groups (71% vs. 75%, p=n.s.). By VAD support hemodynamic and metabolic parameters could be reversed more effectively in comparison to IABP treatment (Table, * denotes p<0.05). However, complications as bleeding requiring transfusion of blood components (n=16 vs. n=8, p=0.005), limb ischemia (n=6 vs. n=0, p=0.007), or elevated temperature >38.5°C (n=16 vs. n=10, p=0.04) were encountered more frequently after VAD support. 30-day-mortality was similar (IABP 45% vs. VAD 39%, log-rank, p=0.70).
Conclusions By a newly developed VAD hemodynamic and metabolic parameters can be reversed more effectively as by standard treatment. However, so far there is no mortality benefit, which may be accounted to more complications by the highly invasive procedure and the extracorporeal support. Table) . Of the 77 pts without HF, 43 had BNP levels > 100, and 23 had BNP > 200 pg/ml. These patients were elderly, 78% had a pulmonary process, and 82% had infection and sepsis. 82% had evidence of pulmonary hypertension. Conclusion: Serum BNP testing has an increased false positive rate outside the clinical trial setting and may lead to unnecessary and costly cardiac testing. BNP testing has not been studied in patients with edema, however this was a common presentation in our population. The recommended cutoff of 100 may be too low for routine use. 
